As of late April 2026, Cramer has shifted his focus toward healthcare and "legacy" companies effectively deploying AI.
: There is a documented increase in short-selling activity immediately following his buy recommendations as professional investors exploit the temporary overpricing. Recent "Buy" Recommendations (April 2026) cramer buy
: Noted for stabilizing leadership and strong earnings. As of late April 2026, Cramer has shifted
: Cited for its strong position as rivals scale back. As of late April 2026
: Praised for its robust drug pipeline and use of AI in cancer treatments.